General information about company
Scrip code*		523144
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE442D01010
Name of company		MEDI-CAPS LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2025
Date of end of financial year		31-03-2026
Date of board meeting when results were approved		21-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		14-05-2026
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Fourth quarter
Nature of report standalone or consolidated		Consolidated
Whether results are audited or unaudited for the quarter ended		Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Audited
Segment Reporting		Multi segment
Description of single segment
Start date and time of board meeting		21-05-2026 15:00
End date and time of board meeting		21-05-2026 15:55
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	344.94	1244.85
	Other income	558.58	820.79
	Total income	903.52	2065.64
2	Expenses
(a)	Cost of materials consumed	118.09	543.87
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	35.72	20.01
(d)	Employee benefit expense	216.95	774.44
(e)	Finance costs	0	1.3
(f)	Depreciation, depletion and amortisation expense	49.78	180.82
(g)	Other Expenses
1	Power Cost	45.97	189.08
2	Freight Expenses	16.78	103.01
3	Other Expenses	117.49	555.45
	Total other expenses	180.24	847.54
	Total expenses	600.78	2367.98
3	Total profit before exceptional items and tax	302.74	-302.34
4	Exceptional items	0	0
5	Total profit before tax	302.74	-302.34
6	Tax expense
7	Current tax	0	2.85
8	Deferred tax	-1.44	-1.44
9	Total tax expenses	-1.44	1.41
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	304.18	-303.75
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	304.18	-303.75
17	Other comprehensive income net of taxes	-787.7	-662.74
18	Total Comprehensive Income for the period	-483.52	-966.49
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	304.18	-303.75
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	-483.52	-966.49
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	1247	1247
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve		9914.18
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	2.44	-2.44
	Diluted earnings (loss) per share from continuing operations	2.44	-2.44
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	2.44	-2.44
	Diluted earnings (loss) per share from continuing and discontinued operations	2.44	-2.44
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Text Block

Textual Information(4)

NOTES:

1. The above standalone and consolidated Audited financial results for the Quarter and Financial Year ended March 31, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on May 21, 2026. The statutory auditors have expressed an unmodified opinion for financial results for the year ended 31st March,2026 therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion.

2. This statement has been prepared in accordance with Guideline issued by SEBI ,the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.

5. The standalone and consolidated statement of assets & Liabilities as at March 31, 2026 is annexed with the results along with cash flow statements.

6. The Company has generated revenue from operations of Rs. 53.35 Lacs during this quarter and Rs. 230.59 Lacs during F.Y. 2025-26 on standalone basis. The Company has incurred a loss of Rs. -13.87 Lacs in this year due to volatile market conditions of real estate market. On the other hand, on consolidated basis the Company has generated revenue of Rs. 344.94 lacs in this quarter and revenue of Rs. 1244.85 lacs this year. The company has incurred losses of Rs. -303.75 lacs in this year, due to unstable political conditions in company’s major market i.e. USA.

7. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

8. The Statement includes the results for the quarters ended March 31, 2026 and March 31, 2025 and being the balancing figure of the audited figures in respect of the full financial year ended March 31, 2026 and March 31, 2025 and the published year to date figures upto the third quarter of the respective financial years, the results of which were subjected to ‘limited review’.

9. The aforesaid audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.

DATE: 21.05.2026 For and on behalf of the Board of Directors of
PLACE: INDORE MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	2707.25
	Capital work-in-progress	0
	Investment property	0
	Goodwill	2814.15
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	1248.69
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets
1
2
3
4
5
	Details of other non-current financial assets
	Total of other non-current financial assets
	Total non-current financial assets	1248.69
	Deferred tax assets (net)
	Other non-current assets
1	Security Deposits	73.91
2
3
4
5
	Details of other non-current assets
	Total of other non-current assets	73.91
	Total non-current assets	6844
2	Current assets
	Inventories	294.21
	Current financial asset
	Current investments	2341.12
	Trade receivables, current	692.12
	Cash and cash equivalents	50.31
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets
1
2
3
4
5
	Details of other current financial assets
	Total of Other current financial assets
	Total current financial assets	3083.55
	Current tax assets (net)
	Other current assets
1	Advance to Suppliers & Others	228.09
2	Advance Tax & TDS /TCS Receivable	215.7
3	MAT Credit Entitlement	207.99
4	Deposit with Banks (FDR	643.6
5	Other current assets	29.28
	Details of other current assets
	Total of other current assets	1324.66
	Total current assets	4702.42
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	11546.42
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	1247
	Other equity	9914.18
	Total equity attributable to owners of parent	11161.18
	Non controlling interest
	Total equity	11161.18
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade Payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities
1
2
3
4
5
	Details of other non-current financial liabilities
	Total of other non-current financial liabilities
	Total non-current financial liabilities	0
	Provisions, non-current	74.07
	Deferred tax liabilities (net)	40.01
	Deferred government grants, Non-current	0
	Other non-current liabilities
1
2
3
4
5
	Details of other non-current liabilities
	Total of other non-current liabilities
	Total non-current liabilities	114.08
	Current liabilities
	Current financial liabilities
	Borrowings, current	0
	Trade Payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	47.71
	Total Trade payable	47.71
	Other current financial liabilities
1
2
3
4
5
	Details of other current financial liabilities
	Total of other current financial liabilities
	Total current financial liabilities	47.71
	Other current liabilities
1	Revenue Received in Advance	108.83
2	Outstanding Liabilities	53.47
3	Unpaid Salary & Wages (Provision)	30.89
4	Bonus Payable	12.51
5	Other current liabilities	17.75
	Details of other current liabilities
	Total of other current liabilities	223.45
	Provisions, current	0
	Current tax liabilities (Net)	0
	Deferred government grants, Current
	Total current liabilities	271.16
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	385.24
	Total equity and liabilities	11546.42
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Pharma Devision	291.59	1014.26
2	Real Estate Devision	53.35	230.59
3	Other	0	0
	Total Segment Revenue	344.94	1244.85
	Less: Inter segment revenue
	Revenue from operations	344.94	1244.85
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Pharma Devision	335.47	-288.58
2	Real Estate Devision	-32.73	-12.46
3	Other	0	0
	Total Profit before tax	302.74	-301.04
	i. Finance cost	0	1.3
	ii. Other Unallocable Expenditure net off Unallocable income	0	0
	Profit before tax	302.74	-302.34
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Pharma Devision	4812.41	4812.41
2	Real Estate Devision	6734.01	6734.01
3	Other	0	0
	Total Segment Asset	11546.42	11546.42
	Un-allocable Assets	0	0
	Net Segment Asset	11546.42	11546.42
4	Segment Liabilities
	Segment Liabilities
1	Pharma Devision	322.43	322.43
2	Real Estate Devision	62.82	62.82
3	Other	0	0
	Total Segment Liabilities	385.25	385.25
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	385.25	385.25
	Disclosure of notes on segments

Other Comprehensive Income
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to statement of profit & loss	-787.70	-662.74
	Total Amount of items that will not be reclassified to profit and loss	-787.70	-662.74
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	-787.70	-662.74

Cash flow statement, indirect
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
Part I	Blue color marked fields are non-mandatory.
1	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax	-302.34
2	Adjustments for reconcile profit (loss)
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	25.83
	Adjustments for decrease (increase) in trade receivables, current	186.91
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-92.66
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	0
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-27.98
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	180.82
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	-662.74
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-389.82
	Net cash flows from (used in) operations	-692.16
	Dividends received	-7.23
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	2.85
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	-702.24
3	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	788.76
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	84.64
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	7.23
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	711.35
4	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	0
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	9.11
5	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	9.11
	Cash and cash equivalents cash flow statement at beginning of period	41.2
	Cash and cash equivalents cash flow statement at end of period	50.31

Details of Impact of Audit Qualification
Whether results are audited or unaudited		Audited
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Rawka & Associates	Yes	30-04-2029

General information about company

Financial Results – Ind-AS

Text Block

Statement of Asset and Liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Other Comprehensive Income

Cash flow statement, indirect

Details of Impact of Audit Qualification